Press Release **For Immediate Release**

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene Cream, 0.005%

Mumbai, May 04, 2015: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Calcipotriene Cream, 0.005%, the therapeutic equivalent of Dovonex® Topical Cream, 0.005% of Leo Pharma A/S. Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA. The patents listed in the Orange Book for Dovonex® Cream are scheduled to expire on June 9, 2015.

Dovonex® is indicated for the treatment of plaque psoriasis. According to IMS Health sales data for the 12 month period ending March 2015, the Dovonex® market achieved annual sales of approximately USD 92.8 million*.

Glenmark's current portfolio consists of 97 products authorized for distribution in the U.S. marketplace and 67 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Dovonex® is a registered trademark of Leo Pharmaceutical Products Ltd.

*IMS Health National Sales Perspectives: Retail & Non-Retail, March 2015

About Glenmark Pharmaceuticals:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma& Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers.

For further information, please contact:

Jason D'Souza / Rajdeep Barooah

Glenmark, Mumbai, India Tel: [+91 22] 40189919/984

Email: corpcomm@glenmarkpharma.com